Search Results

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli Lilly and a showdown with Novartis.

Numerous GLP-1 RA and SGLT2i presentations touted their clinical results, providing continued excitement for our BETonMACE program, which observed a non-prespecified 63% reduction in MACE and heart failure hazard among patients taking next-generation glucose lowering drugs

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than Humira’s 20% at the same time point.

Glaukos Corporation announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.

TCB strengthens its capital markets and operational advisory businesses with the addition of numerous notable Strategic Advisory Board members from across the healthcare and life sciences sectors

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to announce that allowance has been granted for the Composition of Matter of its PharmAla-1 (P-1) molecule by the US Patent and Trademark Office (USPTO).

Glaukos Corporation (NYSE: GKOS) announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 3-6, 2023 in San Francisco, CA.